|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||28.70 - 28.88|
|52 Week Range||28.48 - 36.82|
|PE Ratio (TTM)||21.71|
|Forward Dividend & Yield||1.11 (3.82%)|
|1y Target Est||N/A|
OTCQX: RHHBY) announced today that its new hematology testing solution, the cobas m 511 integrated hematology analyzer, has received 510(k) clearance from the U.S. Food and Drug Administration (FDA). The cobas m 511 analyzer, featuring patented Bloodhound® technology, is designed to address the challenges of hematology testing by combining a cell counter, slide maker and stainer and a digital morphology analyzer into one integrated solution.
-- HITRUST CSF® certification granted for NAVIFY™ Tumor Board solution -- Belmont site received ISO/IEC 27001 certification -- Commitment to Patient Data Safety and Cybersecurity BELMONT, Calif. and BASEL, ...
TUCSON, Ariz. , March 1, 2018 /PRNewswire/ -- Breakthrough discoveries in the field of cancer and health technology are the focus of the 14th annual Tucson Symposium, March 13-14 . The conference, sponsored ...
Genentech, a member of the Roche Group , announced today that the U.S. Food and Drug Administration has accepted the company’s Supplemental Biolog
OTCQX: RHHBY) announced today that it has received FDA clearance for the cobas® Factor II and Factor V Test for use on the cobas® 4800 system. The test enables laboratories to simultaneously assess Factor II and Factor V gene mutations from a single patient sample, which can reduce hands-on time when testing patients for inherited thrombophilia. "Patients and their caregivers rely on genetic test results to accurately manage their risk for blood clots," said Uwe Oberlaender, head of Roche Molecular Systems.
OTCQX: RHHBY) announced today the establishment of a strategic alliance with Wisconsin Diagnostic Laboratories of Milwaukee, Wisc., that designates the institution as a Roche Molecular Center of Excellence (MCOE). Established in 2002, Roche's MCOE network enables non-competing regional laboratories across the U.S. to collaborate and capitalize on scientific knowledge in molecular testing and, in turn, help accelerate the advancement of new test methods and technology. Wisconsin Diagnostic Laboratories serves more than 30 hospitals, 500 long-term care facilities and 100 outreach practices in Wisconsin and the Chicago area.
Genentech, a member of the Roche Group , today announced encouraging results from the Phase II BOULEVARD study. In people with vision loss from diabetic macular edema , treatment with intravitreal RG7716 resulted in clinically meaningful and statistically significant improvements in visual acuity gains compared with ranibizumab alone.
Genentech, a member of the Roche Group , today announced results from the positive Phase III IMmotion151 study of TECENTRIQ® and Avastin® as a first-line treatment for advanced or metastatic renal cell carcinoma .
NEW YORK, NY / ACCESSWIRE / February 1, 2018 / Roche Holding AG (OTCQB: RHHBY ) will be discussing their earnings results in their Q3 Earnings Call to be held on February 1, 2018 at 10:00 AM Eastern Time. ...
-- The VENTANA MMR IHC Panel1 helps differentiate between sporadic colorectal cancer and probable Lynch syndrome, a hereditary form of colorectal cancer -- Lynch syndrome results in a 50 to 80 percent ...
OTCQX: RHHBY) to make precision medicine a reality for more cancer patients and their healthcare providers. Syapse and Roche will work jointly to develop software products and analytics solutions that empower healthcare providers with the tools and insights they need to practice precision medicine at scale, with the goal of improving patient outcomes and health-related quality of life.
GE Healthcare has entered into a strategic, long-term partnership with Roche to jointly develop and co-market digital clinical decision support solutions.
Data Integration Services Crucial to Decision Support in Oncology BASEL, Switzerland , Dec. 22, 2017 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced a collaborative services agreement ...
Roche and Ignyta, Inc. today announced they have entered into a definitive merger agreement for Roche to fully acquire Ignyta at a price of US$ 27.00 per share in an all-cash transaction.
Genentech, a member of the Roche Group , today announced the U.S. Food and Drug Administration has approved Perjeta® , in combination with Herceptin® and chemotherapy , for adjuvant treatment of HER2-positive early breast cancer at high risk of recurrence.
Genentech, a member of the Roche Group , today announced the first results from the pivotal Phase III MURANO study evaluating Venclexta™ plus Rituxan® compared to bendamustine plus Rituxan for the treatment of people with relapsed or refractory chronic lymphocytic leukemia .
OTCQX: RHHBY) announced today that it has received a Military Friendly® Employers Gold Award by Victory Media in the Over $1B revenue category. First published in 2003, Military Friendly® Employers is the most comprehensive, powerful resource for veterans today. Each year, the list of Military Friendly® Employers is provided to service members and their families, helping them discover the best post-military career opportunities available.
Genentech, a member of the Roche Group , today announced that the Phase III IMmotion151 study met its co-primary endpoint of investigator-assessed progression-free survival and demonstrated that the combination of TECENTRIQ® and Avastin® provided a statistically significant and clinically meaningful reduction in the risk of disease worsening or death in people whose disease expressed the PD-L1 protein ...
Genentech, a member of the Roche Group , announced today positive results from the randomized Phase II GO29365 study that compared polatuzumab vedotin in combination with bendamustine plus Rituxan® against BR alone in people with relapsed or refractory diffuse large B-cell lymphoma who are not candidates for hematopoietic stem cell transplant.
Genentech, a member of the Roche Group , announced today that new data from the ongoing HEMLIBRA® clinical development program were presented at the 59th American Society of Hematology Annual Meeting.
OTCQX: RHHBY) has been honored with a Glassdoor Employees' Choice Award, recognizing the Best Places to Work in 2018. The Employees' Choice Awards program, now in its 10th year, relies solely on the input of employees, who elect to provide feedback on their jobs, work environments and companies via Glassdoor. To help people find companies that stand out from the pack, the Glassdoor Employees' Choice Awards recognize employers that are truly Best Places to Work because they're determined by those who really know best - the employees," said Robert Hohman, Glassdoor CEO and co-founder.
Genentech, a member of the Roche Group , announced today positive interim results from the Phase III HAVEN 4 study evaluating HEMLIBRA® prophylaxis dosed once every four weeks in adults and adolescents with hemophilia A with and without inhibitors to factor VIII.
Genentech, a member of the Roche Group , today announced results from the positive, pivotal Phase III IMpower150 study of TECENTRIQ® and Avastin® plus chemotherapy in people with previously untreated, advanced non-squamous non-small cell lung cancer .
Genentech, a member of the Roche Group , announced today that the U.S. Food and Drug Administration has granted full approval for Avastin® for the treatment of adults with glioblastoma that progressed following prior therapy .
INDIANAPOLIS , Dec. 1, 2017 /PRNewswire/ -- Company supports FDA recommendation for lab, clinician and patient education about reporting all prescription medication and supplements prior to blood draws. ...